Vandongen R, Barden A, Tunney A
Aust N Z J Med. 1980 Jun;10(3):300-4. doi: 10.1111/j.1445-5994.1980.tb04074.x.
The response of plasma renin activity (PRA) to frusemide, 40 mg given intravenously, was examined before and after oral propranolol 160 mg daily for seven days in normal and hypertensive subjects. Although basal PRA was reduced in many cases, the increase following frusemide was essentially unaltered by propranolol therapy. Evidence is presented that adequate beta adrenoceptor blockade was attained in these studies. Increasing the dose of propranolol to 240 mg daily for seven days in two subjects did not alter renin responsiveness to frusemide. Stimulation of renin release by oral frusemide, examined in one subject, was also unaltered by propranolol therapy. These findings indicate that enhancement of renin activity associated with diuretic use may not be prevented by concurrent propranolol administration. Limitation of the hypotensive action of combined beta blocker-diuretic therapy can therefore be expected. The fact that the renin stimulating effect of frusemide is preserved during beta blockade indicates that this procedure can be used in the investigation of hypertension even in those patients in whom discontinuation of beta blocking treatment may be undesirable.
在正常人和高血压患者中,在口服每日160毫克普萘洛尔共七天之前和之后,检测了静脉注射40毫克速尿后血浆肾素活性(PRA)的反应。尽管在许多情况下基础PRA降低,但速尿后的升高基本上未因普萘洛尔治疗而改变。有证据表明在这些研究中已实现了充分的β肾上腺素能受体阻滞。在两名受试者中将普萘洛尔剂量增加至每日240毫克共七天,并未改变肾素对速尿的反应性。在一名受试者中检测的口服速尿对肾素释放的刺激,也未因普萘洛尔治疗而改变。这些发现表明,同时使用普萘洛尔可能无法预防与利尿剂使用相关的肾素活性增强。因此,可以预期β受体阻滞剂 - 利尿剂联合治疗的降压作用会受到限制。速尿的肾素刺激作用在β受体阻滞期间得以保留,这一事实表明,即使在那些可能不希望停用β受体阻滞剂治疗的患者中,该方法也可用于高血压的研究。